



# UNITED STATED DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAME	DINVENTOR		ATTORNEY DOCKET NO.
09/383,054	08/25/99	EDWARDS		D	AIR-108PA
-		HM12/0426	乛	EXAMINER	
CAROLYN S. ELMORE			PULLIA	М, А	
HAMILTON BROOK SMITH & REYNOLDS P C			ART UNIT	PAPER NUMBER	
	MILITIA DRIVE INGTON MA 02421-4799			1615	5
				DATE MAILED:	04/26/00

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

	Application No.	Applicant(s)				
Office Action Summary	09/383,054	EDWARDS ET AL.				
Office Action Summary	Examiner	Art Unit				
	Amy E Pulliam	1615				
The MAILING DATE of this communication appe Period for Reply	ars on the cover sheet with the co	rrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.	' IS SET TO EXPIRE 3 MONTH(	S) FROM				
<ul> <li>Extensions of time may be available under the provisions of 37 of after SIX (6) MONTHS from the mailing date of this communication.</li> <li>If the period for reply specified above is less than thirty (30) days be considered timely.</li> <li>If NO period for reply is specified above, the maximum statutory communication.</li> <li>Failure to reply within the set or extended period for reply will, by Status</li> </ul>	cation.  s, a reply within the statutory minimum of period will apply and will expire SIX (6) N	thirty (30) days will				
1) Responsive to communication(s) filed on <u>28 February 2000</u> .						
2a) ☐ This action is <b>FINAL</b> . 2b) ☑ Thi	s action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the ments is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>1-49</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdraw	wn from consideration.					
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-49</u> is/are rejected.						
7) Claim(s) is/are objected to.	•					
8) Claims are subject to restriction and/or	election requirement.					
Application Papers						
9) The specification is objected to by the Examine	r.					
10) The drawing(s) filed on is/are objected to by the Examiner.						
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved.						
12) The oath or declaration is objected to by the Ex	aminer.					
Priority under 35 U.S.C. § 119						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).						
a) All b) Some * c) None of the CERTIFIED copies of the priority documents have been:						
1. received.						
2. received in Application No. (Series Code	e / Serial Number)					
3. received in this National Stage applicatio	n from the International Bureau (	PCT Rule 17.2(a)).				
* See the attached detailed Office action for a list of	of the certified copies not receive	d.				
14)⊠ Acknowledgement is made of a claim for dome	stic priority under 35 U.S.C. & 11	9(e).				
Attachment(s)						
<ul> <li>14)  Notice of References Cited (PTO-892)</li> <li>15)  Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>16)  Information Disclosure Statement(s) (PTO-1449) Paper No(s) 4</li> </ul>	18) Notice of Informal	y (PTO-413) Paper No(s) Patent Application (PTO-152)				

Application/Control Number: 09/383,054

Art Unit: 1615

### **DETAILED ACTION**

Receipt is acknowledged of the Declaration, Filing Fee, and Surcharge, received November 1, 1999, as well as the Information Disclosure Statement, received February 28, 2000.

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-9, 13-18, 22-34, 38-42, and 46-49 are rejected under 35 U.S.C. 102(b) as being anticipated by WO 91/16882 to Durrani *et al.*. Durrani *et al.* disclose a process to directly spray dry a drug/ lipid powder composition comprising preparing an aqueous solution containing a drug and a lipid containing ethanol solution. The mixture is then spray dried to get particles (page 40, claim 1). Durrani *et al.* further teach that the drug may be selected from a group which includes insulin, granulocyte colony stimulating factor, inferons, growth factors, calcitonin, and interleukins (page 40, claim 2), as well as peptide hormones, and lung surfactant proteins (p 10-11). Durrani *et al.* further teach that the lipid may selected from the group consisting of phosphatidylglycerol, phosphatidylcholine, phosphatidylinosotil, phosphatidylethanoemines, and

Application/Control Number: 09/383,054

Art Unit: 1615

phosphatidylserine (page 41, claim 4). Lastly, Durrani et al. teach that the diameter of the resulting particles is between 0.1 and 20 microns (page 14, line 30).

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-49 are rejected under 35 U.S.C. 103(a) as being unpatentable over WO 91/16882 to Durrani *et al.* as applied to claims 1-9, 13-18, 22-34, 38-42, and 46-49 above. Durrani *et al.* do not disclose the percent protein integrity or the tap density of the spray dried particles. However, based on the fact that Durrani *et al.* disclose the same components in the spray dried particles, it is the position of the examiner that the protein integrity and tap density are inherent characteristics, and would be the same as those claimed by applicant, absent the presentation of some unusual and/ or unexpected results. Further, on page 8 of the specification, applicant states that spray dried particles which have decreased stability are those without a phospholipid or with just an aqueous solvent. Durrani *et al.* teach the inclusion of phospholipids and organic solvents in their particles, so therefore, their particles would have the improved characteristics as claimed by applicant.

Art Unit: 1615

### Conclusion

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy Pulliam, whose telephone number is (703) 308-4710. The examiner can normally be reached Monday to Friday from 7:30 am to 4:00 pm.

If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Thurman Page, can be reached at (703) 308-2927.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the group receptionist whose telephone number is (703) 308-1234.

THURMAIN K. PAGE UPERASURO POTENT EXAMINER

TECHNOLOGY CENTER 1600